Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Fisher Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 176.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 282,288 shares of the company’s stock after buying an additional 180,029 shares during the period. Fisher Asset Management LLC owned about 0.37% of Kiniksa Pharmaceuticals International worth $10,961,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of KNSA. EverSource Wealth Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $32,000. Nordea Investment Management AB increased its holdings in Kiniksa Pharmaceuticals International by 0.7% during the 3rd quarter. Nordea Investment Management AB now owns 131,074 shares of the company’s stock valued at $5,016,000 after purchasing an additional 914 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the last quarter. Finally, Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth $31,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $47.27 on Thursday. The company has a market capitalization of $3.58 billion, a P/E ratio of 63.88 and a beta of 0.06. The business has a 50-day moving average of $43.16 and a two-hundred day moving average of $40.09. Kiniksa Pharmaceuticals International, plc has a 1 year low of $18.25 and a 1 year high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company’s revenue was up 65.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. This trade represents a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the sale, the chief operating officer owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 123,623 shares of company stock worth $5,236,389 over the last ninety days. 53.48% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

KNSA has been the subject of several research reports. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.